265. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer in respect of Skyclarys; whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and the HSE management became directly involved in the reimbursement or commercial process; the chronology of the process through to the reimbursement decision; and the objective factors which informed the HSE's approach and final decision, without requiring disclosure of commercially confidential net pricing, in tabular form. [70809/26]

Summary

265. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer in respect of Skyclarys; whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and the HSE management became directly involved in the reimbursement or commercial process; the chronology of the process through to the reimbursement decision; and the objective factors which informed the HSE's approach and final decision, without requiring disclosure of commercially confidential net pricing, in tabular form. [70809/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 7 October 2026

   Medicinal Products

   265. Deputy David Cullinane asked the Minister for Health following the relevant NCPE recommendation, the number and dates of substantive commercial engagements between the HSE and the manufacturer in respect of Skyclarys; whether the HSE sought an improved commercial offer or made or invited any counterproposal; whether and the HSE management became directly involved in the reimbursement or commercial process; the chronology of the process through to the reimbursement decision; and the objective factors which informed the HSE's approach and final decision, without requiring disclosure of commercially confidential net pricing, in tabular form. [70809/26]

   Source: written

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

2 official files

• Medicinal Products

  xml · EN · 7 October 2026

  ViewDownloadOpen at official source

• Question

  text · EN · 7 October 2026

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• David Cullinane · Asking member
• Health · Health · Addressed to

Related records

No cross-record relationships stored yet.